Sun Pharmaceutical Industries Ltd.
NSE: SUNPHARMA · Pharmaceuticals
Snapshot
Unlock Sun Pharmaceutical Industries Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sun Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets a diverse range of branded and generic formulations alongside active pharmaceutical ingredients. The company operates across numerous therapeutic segments, including cardiology, oncology, dermatology, and neuro-psychiatry, serving both domestic and international markets.
Business Model
The company generates revenue through the sale of complex generic medications, speciality formulations, and active pharmaceutical ingredients. Its business model leverages a broad manufacturing footprint to supply healthcare providers and consumers with affordable medicines across various therapeutic categories.
Growth Outlook
Growth is driven by the expansion of the company's speciality portfolio and the continued penetration of generic markets globally. The firm focuses on high-barrier therapeutic areas to maintain competitive advantage and long-term value creation.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where non-compliance at manufacturing facilities can lead to import alerts or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector exerts significant downward pressure on profit margins across key markets.
- Litigation Risk. As a major pharmaceutical player, the company is susceptible to intellectual property disputes and product liability litigation.
- Currency Volatility. Significant international operations expose the company to fluctuations in foreign exchange rates, which can impact reported earnings.
Start your research today
Unlock AI insights, financials, peers and live data on Sun Pharmaceutical Industries Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹59,911 Cr
TTM · consolidated
NET PROFIT
₹12,117 Cr
TTM · consolidated
EPS
₹50.40
TTM · consolidated
RETURN ON EQUITY
15.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
20.5%
TTM · consolidated
P/E
37.7x
Q1 FY27 · consolidated
EV/EBITDA
22.4x
Q1 FY27 · consolidated
EBITDA MARGIN
33.5%
TTM · consolidated
NET PROFIT MARGIN
19.0%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
| Company | Mkt Cap | P/E | EV/EBITDA | Rev Gr YoY | EBITDA Mgn | ROE | ROCE | 1Y Return |
|---|---|---|---|---|---|---|---|---|
Sun Pharmaceutical Industries Ltd.SUNPHARMA | ₹4.56L Cr | 37.68 | 22.41 | 11.4% | 33.5% | 15.6% | 20.5% | +20.0% |
Divi's Laboratories Ltd.DIVISLAB | ₹2.42L Cr | 82.57 | 54.64 | 16.3% | 39.3% | 18.4% | 23.1% | +48.4% |
Torrent Pharmaceuticals Ltd.TORNTPHARM | ₹1.85L Cr | 77.59 | 38.74 | 32.9% | 32.6% | 27.0% | 15.1% | +34.9% |
Zydus Lifesciences Ltd.ZYDUSLIFE | ₹1.13L Cr | 24.96 | 14.08 | 21.1% | 30.7% | 18.0% | 20.1% | +10.7% |
Cipla Ltd.CIPLA | ₹1.12L Cr | 33.18 | 18.12 | 1.8% | 21.6% | 10.2% | 13.6% | -12.2% |
Laurus Labs Ltd.LAURUSLABS | ₹99,334 Cr | 90.82 | 48.68 | 22.6% | 28.7% | 22.3% | 25.3% | +110.5% |
As of Q1 FY27
Financials
Sun Pharmaceutical Industries Ltd.
NSE: SUNPHARMA · Pharmaceuticals
Snapshot
Unlock Sun Pharmaceutical Industries Ltd.'s vital signs
Growth · Profitability · Valuation · Strength · Conviction
Company Overview
Business
Sun Pharmaceutical Industries Limited is a global pharmaceutical company that develops, manufactures, and markets a diverse range of branded and generic formulations alongside active pharmaceutical ingredients. The company operates across numerous therapeutic segments, including cardiology, oncology, dermatology, and neuro-psychiatry, serving both domestic and international markets.
Business Model
The company generates revenue through the sale of complex generic medications, speciality formulations, and active pharmaceutical ingredients. Its business model leverages a broad manufacturing footprint to supply healthcare providers and consumers with affordable medicines across various therapeutic categories.
Growth Outlook
Growth is driven by the expansion of the company's speciality portfolio and the continued penetration of generic markets globally. The firm focuses on high-barrier therapeutic areas to maintain competitive advantage and long-term value creation.
Key Risks
- Regulatory Compliance. The company faces stringent oversight from global health authorities, where non-compliance at manufacturing facilities can lead to import alerts or product recalls.
- Pricing Pressure. Intense competition in the generic pharmaceutical sector exerts significant downward pressure on profit margins across key markets.
- Litigation Risk. As a major pharmaceutical player, the company is susceptible to intellectual property disputes and product liability litigation.
- Currency Volatility. Significant international operations expose the company to fluctuations in foreign exchange rates, which can impact reported earnings.
Start your research today
Unlock AI insights, financials, peers and live data on Sun Pharmaceutical Industries Ltd. and 5,000+ companies — free.
Key Metrics
REVENUE
₹59,911 Cr
TTM · consolidated
NET PROFIT
₹12,117 Cr
TTM · consolidated
EPS
₹50.40
TTM · consolidated
RETURN ON EQUITY
15.6%
TTM · consolidated
RETURN ON CAPITAL EMPLOYED
20.5%
TTM · consolidated
P/E
37.7x
Q1 FY27 · consolidated
EV/EBITDA
22.4x
Q1 FY27 · consolidated
EBITDA MARGIN
33.5%
TTM · consolidated
NET PROFIT MARGIN
19.0%
Q1 FY27 · consolidated
DEBT TO EQUITY
0.1x
Q1 FY27 · consolidated
Peers · Pharmaceuticals
As of Q1 FY27